Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2)

Matrix Biology

Volumn 30, Issue 7-8, 2011, Pages 404-412

  Xu, Xiaoping ^a   Mikhailova, Margarita ^a   Chen, Zhihua ^a   Pal, Sanjay ^a   Robichaud, Trista K ^a,b   Lafer, Eileen M ^b   Baber, Sam ^a   Steffensen, Bjorn ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

MMP inhibitor; MMP 2; Peptide; ProMMP 2 activation; Protein binding; TIMP 2

Indexed keywords

GELATINASE A; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME BINDING; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; FIBROSARCOMA; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION;

BINDING SITES; CELL LINE, TUMOR; CELL MEMBRANE; CHEMISTRY TECHNIQUES, SYNTHETIC; CULTURE MEDIA, CONDITIONED; ENZYME ACTIVATION; ENZYME INHIBITORS; ENZYME PRECURSORS; ESCHERICHIA COLI; HUMANS; MATRIX METALLOPROTEINASE 2; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; SURFACE PLASMON RESONANCE; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 80053912104     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2011.07.001     Document Type: Article

References (43)

1. Armstrong D.G., Jude E.B. The role of matrix metalloproteinases in wound healing. J. Am. Podiatr. Med. Assoc. 2002, 92:12-18.
2. Bigg H.F., Shi Y.E., Liu Y.E., Steffensen B., Overall C.M. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J. Biol. Chem. 1997, 272:15496-15500.
3. Brown P.D. Matrix metalloproteinase inhibitors. Breast Cancer Res. Treat. 1998, 52:125-136.
4. Butler G.S., Overall C.M. Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics. Biochemistry 2009, 48:10830-10845.
5. Butler G.S., Butler M.J., Atkinson S.J., Will H., Tamura T., van Westrum S.S., Crabbe T., Clements J., d'Ortho M.P., Murphy G. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J. Biol. Chem. 1998, 273:871-880.
6. Collier I.E., Wilhelm S.M., Eisen A.Z., Marmer B.L., Grant G.A., Seltzer J.L., Kronberger A., He C.S., Bauer E.A., Goldberg G.I. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J. Biol. Chem. 1988, 263:6579-6587.
7. Dennis M.S., Eigenbrot C., Skelton N.J., Ultsch M.H., Santell L., Dwyer M.A., O'Connell M.P., Lazarus R.A. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature 2000, 404:465-470.
8. Fernandez C.A., Butterfield C., Jackson G., Moses M.A. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J. Biol. Chem. 2003, 278:40989-40995.
9. Giannobile W.V. Host-response therapeutics for periodontal diseases. J. Periodontol. 2008, 79:1592-1600.
10. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 1997, 74:111-122.
11. Hayakawa T., Yamashita K., Ohuchi E., Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Sci. 1994, 107(Pt 9):2373-2379.
12. Howard E.W., Banda M.J. Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site. J. Biol. Chem. 1991, 266:17972-17977.
13. Izaguirre G., Rezaie A.R., Olson S.T. Engineering functional antithrombin exosites in alpha1-proteinase inhibitor that specifically promote the inhibition of factor Xa and factor IXa. J. Biol. Chem. 2009, 284:1550-1558.
14. Kai H.S., Butler G.S., Morrison C.J., King A.E., Pelman G.R., Overall C.M. Utilization of a novel recombinant myoglobin fusion protein expression system to characterize the tissue inhibitor of metalloproteinase (TIMP)-4 and TIMP-2 C-terminal domain and tails by mutagenesis. The importance of acidic residues in binding the MMP-2 hemopexin C-domain. J. Biol. Chem. 2002, 277:48696-48707.
15. Knauper V., Murphy G. Methods for studying activation of matrix metalloproteinases. Methods Mol. Biol. 2001, 151:377-387.
16. Lambert E., Dasse E., Haye B., Petitfrere E. TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol. 2004, 49:187-198.
17. Lauer-Fields J.L., Whitehead J.K., Li S., Hammer R.P., Brew K., Fields G.B. Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J. Biol. Chem. 2008, 283:20087-20095.
18. Lauer-Fields J.L., Chalmers M.J., Busby S.A., Minond D., Griffin P.R., Fields G.B. Identification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity. J. Biol. Chem. 2009, 284:24017-24024.
19. Lauer-Fields J.L., Minond D., Chase P.S., Baillargeon P.E., Saldanha S.A., Stawikowska R., Hodder P., Fields G.B. High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg. Med. Chem. 2009, 17:990-1005.
20. Manning M., Stoev S., Chini B., Durroux T., Mouillac B., Guillon G. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog. Brain Res. 2008, 170:473-512.
21. Morgunova E., Tuuttila A., Bergmann U., Tryggvason K. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc. Natl. Acad. Sci. U.S.A 2002, 99:7414-7419.
22. Murphy G., Houbrechts A., Cockett M.I., Williamson R.A., O'Shea M., Docherty A.J. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 1991, 30:8097-8102.
23. Murphy G., Stanton H., Cowell S., Butler G., Knauper V., Atkinson S., Gavrilovic J. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999, 107:38-44.
24. Olson M.W., Gervasi D.C., Mobashery S., Fridman R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J. Biol. Chem. 1997, 272:29975-29983.
25. Overall C.M., Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2002, 2:657-672.
26. Overall C.M., King A.E., Sam D.K., Ong A.D., Lau T.T., Wallon U.M., DeClerck Y.A., Atherstone J. Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase A by site-directed mutagenesis. The hierarchical role in binding TIMP-2 of the unique cationic clusters of hemopexin modules III and IV. J. Biol. Chem. 1999, 274:4421-4429.
27. Overall C.M., Tam E., McQuibban G.A., Morrison C., Wallon U.M., Bigg H.F., King A.E., Roberts C.R. Domain interactions in the gelatinase A.TIMP-2.MT1-MMP activation complex. The ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation. J. Biol. Chem. 2000, 275:39497-39506.
28. Roberge M., Santell L., Dennis M.S., Eigenbrot C., Dwyer M.A., Lazarus R.A. A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors. Biochemistry 2001, 40:9522-9531.
29. Rosenthal E.L., Matrisian L.M. Matrix metalloproteases in head and neck cancer. Head Neck 2006, 28:639-648.
30. Scheer J.M., Romanowski M.J., Wells J.A. A common allosteric site and mechanism in caspases. Proc. Natl. Acad. Sci. U.S.A 2006, 103:7595-7600.
31. Sorsa T., Tjaderhane L., Konttinen Y.T., Lauhio A., Salo T., Lee H.M., Golub L.M., Brown D.L., Mantyla P. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann. Med. 2006, 38:306-321.
32. Stanley C.M., Wang Y., Pal S., Klebe R.J., Harkless L.B., Xu X., Chen Z., Steffensen B. Fibronectin fragmentation is a feature of periodontal disease sites and diabetic foot and leg wounds and modifies cell behavior. J. Periodontol. 2008, 79:861-875.
33. Steffensen B., Wallon U.M., Overall C.M. Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. J. Biol. Chem. 1995, 270:11555-11566.
34. Steffensen B., Xu X., Martin P.A., Zardeneta G. Human fibronectin and MMP-2 collagen binding domains compete for collagen binding sites and modify cellular activation of MMP-2. Matrix Biol. 2002, 21:399-414.
35. Strongin A.Y., Marmer B.L., Grant G.A., Goldberg G.I. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J. Biol. Chem. 1993, 268:14033-14039.
36. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 1995, 270:5331-5338.
37. Willenbrock F., Crabbe T., Slocombe P.M., Sutton C.W., Docherty A.J., Cockett M.I., O'Shea M., Brocklehurst K., Phillips I.R., Murphy G. The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. Biochemistry 1993, 32:4330-4337.
38. Williamson R.A., Marston F.A., Angal S., Koklitis P., Panico M., Morris H.R., Carne A.F., Smith B.J., Harris T.J., Freedman R.B. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem. J. 1990, 268:267-274.
39. Worley J.R., Thompkins P.B., Lee M.H., Hutton M., Soloway P., Edwards D.R., Murphy G., Knauper V. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Biochem. J. 2003, 372:799-809.
40. Xu X., Wang Y., Lauer-Fields J.L., Fields G.B., Steffensen B. Contributions of the MMP-2 collagen binding domain to gelatin cleavage. Substrate binding via the collagen binding domain is required for hydrolysis of gelatin but not short peptides. Matrix Biol. 2004, 23:171-181.
41. Xu X., Chen Z., Wang Y., Yamada Y., Steffensen B. Functional basis for the overlap in ligand interactions and substrate specificities of matrix metalloproteinases-9 and -2. Biochem. J. 2005, 392:127-134.
42. Xu X., Wang Y., Chen Z., Sternlicht M.D., Hidalgo M., Steffensen B. Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Res. 2005, 65:130-136.
43. Xu X., Chen Z., Wang Y., Bonewald L., Steffensen B. Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions. Biochem. J. 2007, 406:147-155.